Tuesday 20 October 2026
Export INCY’s income statement to Excel — free account
Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
116.27
3.02
+2.67%
Follow INCY
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
182.71 | 0.00 | 122.29 | 41.98 | 0.00 | 17.11 | 51.66 | 24.51 | 222.81 | 14.97 |
Piotroski F-Score |
6 | 4 | 7 | 5 | 4 | 4 | 4 | 5 | 5 | 9 |
P/S ratio |
17.39 | 13.44 | 7.18 | 8.69 | 7.11 | 5.42 | 5.20 | 3.96 | 3.37 | 3.75 |
Altman Z-Score |
9.33 | 17.00 | 11.77 | 14.71 | 12.39 | 9.67 | 8.68 | 6.77 | 5.19 | 8.57 |
P/FCF ratio |
104.20 | 0.00 | 51.40 | 29.67 | 0.00 | 28.46 | 19.80 | 32.60 | 60.83 | 14.50 |
Altman Z″-Score (non-manufacturers) |
0.51 | 2.24 | 4.31 | 6.49 | 3.99 | 6.70 | 6.84 | 7.41 | 3.17 | 7.90 |
Beneish M-Score |
(1.52) | (2.08) | (2.79) | (2.82) | (2.20) | (1.98) | (3.11) | (2.20) | (2.69) | (2.43) |
P/Operating CF |
203.68 | (231.22) | 161.09 | 142.58 | 176.74 | 140.26 | 62.26 | 99.08 | 37.52 | 35.49 |
P/B ratio |
45.83 | 12.66 | 7.01 | 7.22 | 7.26 | 4.29 | 4.04 | 2.82 | 4.15 | 3.73 |
Price to Tangible BV |
3,535.68 | 16.67 | 8.69 | 8.34 | 8.31 | 4.67 | 4.32 | 2.98 | 4.50 | 3.92 |
EV/Sales |
17.24 | 12.69 | 6.43 | 7.74 | 6.45 | 4.65 | 4.26 | 2.98 | 2.87 | 3.06 |
EV/EBITDA |
93.73 | 0.00 | 65.65 | 36.58 | 0.00 | 21.56 | 22.34 | 15.67 | 80.95 | 9.79 |
EV/Operating CF |
62.56 | (209.64) | 35.96 | 23.50 | (138.13) | 18.51 | 14.91 | 22.20 | 36.36 | 11.14 |
EV/FCF |
103.35 | (95.56) | 46.02 | 26.40 | (55.17) | 24.41 | 16.21 | 24.55 | 51.84 | 11.84 |
Quick Ratio |
3.50 | 3.83 | 4.11 | 4.73 | 3.62 | 3.47 | 3.36 | 3.55 | 1.83 | 3.04 |
Current Ratio |
3.64 | 4.01 | 4.31 | 4.83 | 3.74 | 3.65 | 3.54 | 3.75 | 1.97 | 3.32 |
Net Debt/EBITDA |
(0.77) | 5.99 | (7.71) | (4.53) | 8.35 | (3.60) | (4.96) | (5.16) | (14.11) | (2.21) |
Debt/Assets |
39.76% | 1.04% | 0.66% | 1.47% | 0.91% | 0.64% | 0.52% | 0.43% | 0.62% | 0.43% |
Debt/Equity |
1.55 | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Asset Turnover |
0.84 | 0.78 | 0.76 | 0.71 | 0.76 | 0.70 | 0.63 | 0.59 | 0.69 | 0.83 |
Operating CF/Net income |
2.92 | 0.30 | 3.07 | 1.59 | 0.42 | 0.79 | 2.85 | 0.83 | 10.28 | 1.10 |
Capex/Depreciation |
(2.06) | (2.13) | (1.34) | (1.43) | (3.62) | (3.13) | (1.15) | (0.57) | (1.12) | (0.90) |
Interest Coverage |
3.74 | (35.27) | 83.75 | 216.71 | (121.29) | 307.01 | 217.34 | 243.25 | 26.91 | 623.91 |
| 35.29% | (30.55%) | 6.16% | 19.76% | (11.35%) | 29.73% | 8.37% | 12.50% | 0.76% | 29.87% | |
| 7.88% | (15.89%) | 4.43% | 14.72% | (8.46%) | 22.33% | 6.32% | 9.47% | 0.53% | 20.75% | |
ROIC |
34.54% | (31.37%) | 15.99% | 47.31% | (19.56%) | 25.19% | 31.19% | 24.81% | 2.90% | 58.55% |
Return on Tangible Assets |
11.73% | (22.54%) | 6.34% | 19.05% | (12.92%) | 31.74% | 9.27% | 14.38% | 1.38% | 30.35% |
Average Days of Receivables |
49.11 | 63.27 | 59.66 | 52.21 | 65.97 | 75.33 | 69.34 | 73.44 | 73.42 | 72.73 |
Research and Development Expense of Revenue |
52.62% | 86.32% | 63.66% | 53.46% | 83.10% | 48.83% | 46.72% | 44.04% | 61.46% | 39.88% |
Selling, General and Administrative Expense of Revenue |
27.43% | 23.84% | 23.08% | 21.71% | 19.38% | 24.77% | 29.52% | 31.27% | 29.29% | 26.77% |
Intangible Assets out of Total Assets |
0.25 | 0.17 | 0.14 | 0.10 | 0.09 | 0.06 | 0.05 | 0.04 | 0.05 | 0.04 |
Share Based Compensation of Revenue |
8.70% | 8.66% | 7.87% | 7.72% | 6.67% | 6.13% | 5.55% | 5.84% | 6.27% | 4.85% |
Graham Net Nets |
(0.01) | 0.04 | 0.08 | 0.09 | 0.07 | 0.12 | 0.15 | 0.21 | 0.09 | 0.17 |
Graham Number |
5.30 | 0.00 | 10.30 | 23.79 | 0.00 | 40.63 | 26.12 | 37.34 | 10.78 | 62.70 |
Earnings Yield |
0.55% | (1.55%) | 0.82% | 2.38% | (1.60%) | 5.84% | 1.94% | 4.08% | 0.45% | 6.68% |
Free Cash Flow Yield |
0.96% | (0.99%) | 1.95% | 3.37% | (1.64%) | 3.51% | 5.05% | 3.07% | 1.64% | 6.90% |
Revenue per Share |
5.89 | 7.51 | 8.86 | 10.04 | 12.23 | 13.55 | 15.29 | 16.53 | 20.48 | 26.34 |
Operating CF per Share |
1.62 | (0.45) | 1.58 | 3.31 | (0.57) | 3.40 | 4.37 | 2.22 | 1.62 | 7.24 |
Capex per Share |
(0.64) | (0.54) | (0.35) | (0.36) | (0.86) | (0.82) | (0.35) | (0.21) | (0.48) | (0.43) |
Free Cash Flow per Share |
0.98 | (1.00) | 1.24 | 2.94 | (1.43) | 2.58 | 4.02 | 2.01 | 1.14 | 6.81 |
Cash per Share |
4.30 | 5.72 | 6.77 | 9.85 | 8.26 | 10.65 | 14.59 | 16.35 | 10.42 | 18.34 |
Shareholders Equity per Share |
2.23 | 7.97 | 9.07 | 12.09 | 11.97 | 17.10 | 19.68 | 23.21 | 16.65 | 26.47 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.23 | 7.97 | 9.07 | 12.09 | 11.97 | 17.10 | 19.68 | 23.21 | 16.65 | 26.47 |
Free Cash Flow |
184.48 | (204.01) | 262.74 | 632.59 | (311.98) | 568.48 | 892.11 | 449.00 | 235.17 | 1,329.63 |
Working Capital |
720.68 | 1,129.46 | 1,406.98 | 1,968.15 | 1,728.70 | 2,264.37 | 2,935.77 | 3,405.02 | 1,597.18 | 3,508.73 |
Capital Expenditures |
(120.28) | (111.02) | (73.48) | (78.06) | (187.38) | (181.01) | (77.83) | (47.49) | (100.16) | (83.87) |
Net Current Asset Value |
(224.95) | 832.90 | 1,112.46 | 1,653.14 | 1,410.24 | 1,955.33 | 2,621.99 | 3,053.13 | 1,242.34 | 3,233.41 |
EV/EBIT |
131.49 | 0.00 | 93.58 | 41.54 | 0.00 | 23.69 | 24.96 | 17.76 | 198.68 | 10.39 |
Capex to Sales |
0.11 | 0.07 | 0.04 | 0.04 | 0.07 | 0.06 | 0.02 | 0.01 | 0.02 | 0.02 |
Price to Operating Income |
132.58 | 0.00 | 104.51 | 46.68 | 0.00 | 27.62 | 30.48 | 23.59 | 233.11 | 12.73 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.35 | 0.20 | 0.17 | 0.14 | 0.09 | 0.08 | 0.09 | 0.11 | 0.12 | 0.13 |
Cash ROIC |
9.82% | (7.22%) | 7.77% | 13.27% | (7.02%) | 9.24% | 11.68% | 5.06% | 4.17% | 15.15% |
Accounts Receivable Turnover |
8.40 | 7.40 | 6.56 | 7.00 | 6.74 | 5.44 | 5.38 | 5.32 | 5.31 | 5.48 |
Accounts Payable Turnover |
1.10 | 1.11 | 1.10 | 1.22 | 1.44 | 1.11 | 0.92 | 1.32 | 2.03 | 1.83 |
Inventory Turnover |
19.76 | 15.01 | 14.00 | 12.44 | 9.44 | 6.81 | 5.92 | 4.86 | 5.12 | 4.65 |
Average Days of Payables |
474.22 | 310.77 | 402.63 | 267.23 | 274.50 | 416.05 | 489.40 | 156.89 | 230.96 | 205.92 |
Days of Inventory on Hand |
25.76 | 29.77 | 27.02 | 36.42 | 45.65 | 67.45 | 74.05 | 90.14 | 68.86 | 99.12 |
Average Receivables |
131.60 | 207.53 | 286.95 | 308.20 | 395.40 | 549.15 | 630.59 | 694.22 | 798.36 | 938.78 |
Average Payables |
52.84 | 71.64 | 85.75 | 93.74 | 91.21 | 135.44 | 224.83 | 193.57 | 153.53 | 203.70 |
Average Inventory |
2.94 | 5.29 | 6.72 | 9.18 | 13.91 | 22.16 | 34.95 | 52.48 | 60.92 | 79.97 |
Average Assets |
1,323.02 | 1,970.59 | 2,474.17 | 3,036.26 | 3,493.83 | 4,247.14 | 5,387.17 | 6,311.55 | 6,113.21 | 6,201.15 |
Average Common Equity |
295.31 | 1,025.05 | 1,778.30 | 2,262.19 | 2,604.84 | 3,190.64 | 4,070.06 | 4,779.98 | 4,318.73 | 4,307.55 |
Columns are period end dates